ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY


Affiliations: 1Haematology, Haematological Malignancy Diagnostic Service (HMDS), St. James’s Institute of Oncology, Leeds, UK; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; 3Medical University of Lodz, Lodz, Poland; 4Dana-Farber Cancer Institute, Boston, MA, USA; 5Washington University School of Medicine, St Louis, MO, USA; 6Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy; 7Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland; 8Hematology Department, St John’s Cancer Centre, Lublin, Poland; 9University Hospital Hradec Králové, Hradec Králové, Czech Republic; 10Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; 11Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, Victoria, Australia; 13Monash Health and Clinical Haematology Unit, Monash University, Clayton, Victoria, Australia; 14Department of Hematology, Copernicus Regional Oncology Centre, Gdansk, Poland; 15Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; 16Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; 17Department of Haematology, Waitemata District Health Board, Takapuna, New Zealand; 18Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy; 19First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic; 20Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA; 21Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; 22Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland; 23Concord Repatriation General Hospital, Concord, NSW, Australia; 24University of Sydney, Sydney, NSW, Australia; 25Department of Hematology, Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda, Milan, Italy; 26Hôpital de Pontchaillou, Rennes, France; 27Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia; 28Hematology Department, Centre Hospitalier Du Mans, Le Mans, France; 29Laboratorio de Citometría de Flujo, Servicio de Hematología y Hemoterapia, Hospital Universitario de Getafe, Getafe, Madrid, Spain; 30Department of Hematology, Jiangsu Province Hospital, Nanjing, China; 31BeiGene USA, San Mateo, CA, USA; 32Alfred Health and Monash University, Melbourne, Victoria, Australia; and 33Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland
**Background:** ZANU is a next-generation Bruton tyrosine kinase inhibitor (BTKi) designed to minimize off-target binding and limit associated side effects that is approved in the US and EU for CLL/SLL. Results from the SEQUOIA study (NCT03336333), at a median follow-up of 26.2 mo, demonstrated superior progression-free survival (PFS) by independent review for ZANU vs BR in pts with treatment-naive (TN) CLL/SLL without (w/o) del(17p); pts with del(17p) treated with ZANU in a separate cohort had similar outcomes to pts w/o del(17p).

**Aims:** To report updated efficacy and safety results from the SEQUOIA study after approximately 18 mo of additional follow-up (data cutoff 31 Oct 2022).

**Methods:** Patients w/o del(17p) were randomized to receive ZANU or BR. Pts with del(17p) were assigned to ZANU monotherapy. Investigator-assessed (INV) PFS, overall survival (OS), overall response rate (ORR) and safety/tolerability were evaluated. Adverse events (AEs) were collected until disease progression or start of next-line therapy.

**Results:** A total of 479 pts w/o del(17p) were randomized to receive ZANU (n=241) or BR (n=238). At a median follow-up of 43.7 mo (range: 0–60 mo), median PFS was not reached for ZANU; however, for BR median PFS was 42.2 mo (HR 0.30; 95% CI: 0.21, 0.43; Figure). At 42 mo, estimated PFS rates were 82.4% for ZANU. With additional follow-up, PFS for ZANU vs BR was now improved for pts with mutated IGHV (HR 0.35; 95% CI: 0.19, 0.64); benefit was also sustained for pts with unmutated IGHV (HR 0.23; 95% CI: 0.14, 0.37) or del(11q) (HR 0.26; 95% CI: 0.13, 0.51). Complete response/complete response with incomplete hematological recovery (CR/CRi) rates in pts w/o del(17p) were 17.4% and 21.8% with ZANU and BR, respectively. While median OS was not reached in either arm, HR for OS was 0.87 (95% CI: 0.50, 1.48) for ZANU vs BR, and estimated 42-month rates were 89.4% and 88.3%, respectively. For 110 pts with del(17p) assigned to ZANU monotherapy, after a median follow-up of 47.9 mo, the estimated 42-month PFS and OS rates were 79.4% and 89.5%, respectively. In this population, the CR/CRi rate was 14.5%.

As of 31 Oct 2022, ZANU treatment was ongoing in 74.7% pts w/o del(17p) and 70.3% pts with del(17p). The most common causes for treatment discontinuation were AEs and progressive disease for both those w/o del(17p) (14.9%, 5.8%) and with del(17p) (13.5%, 13.5%, respectively). AEs of interest (AEI), using pooled terms, were as expected for the class in the pts w/o del(17p) (ZANU vs BR). AEI included any grade (gr) atrial fibrillation/flutter (5.0% vs 2.6%), hypertension (17.5% vs 13.7%), bleeding (48.8% vs 12.3%), infection (72.9% vs 62.6%), anemia (7.1% vs 20.7%), thrombocytopenia (6.3% vs 18.1%), and neutropenia (16.7% vs 56.8%). Additionally, Gr≥3 AEI included bleeding (5.8% vs 1.8%), infection (23.8% vs 22.0%), anemia (0.4% vs 2.2%), thrombocytopenia (2.1% vs 7.9%), and neutropenia (12.5% vs 51.1%).

**Summary/Conclusion:** With extended follow-up in the SEQUOIA study, the efficacy of ZANU was maintained in pts w/o del(17p) with a safety profile aligned with long term follow-up for the BTKi class. In addition to the previously reported benefit in pts with unmutated IGHV, longer follow-up now shows benefit in those with mutated IGHV as well, and pts with del(17p) continue to demonstrate PFS benefits consistent with the randomized cohort. Rates of atrial fibrillation remain low and no new safety signals were identified. ZANU continues to be well tolerated over time with low rates of treatment discontinuation and remains a valuable frontline treatment option for CLL/SLL.
Figure: Progression-Free Survival by Investigator Assessment

HR 0.30 (95% CI: 0.21, 0.43)

Zanubrutinib
BR
Censored

No. of Patients at Risk

| Group          | 241 | 238 | 234 | 230 | 228 | 224 | 219 | 214 | 208 | 205 | 201 | 200 | 190 | 131 | 93  | 33  | 23  | 4   | 3   | 0   |
|----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Zanubrutinib   | 241 | 238 | 234 | 230 | 228 | 224 | 219 | 214 | 208 | 205 | 201 | 200 | 190 | 131 | 93  | 33  | 23  | 4   | 3   | 0   |
| BR             | 238 | 218 | 212 | 201 | 192 | 187 | 180 | 174 | 163 | 157 | 141 | 133 | 113 | 82  | 50  | 18  | 8   | 0   |     |     |

EHA 2023